Bimzelx (bimekizumab)
Research Synopsis
- Bimzelx (bimekizumab) is a novel biologic treatment that targets both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), showing promise for managing plaque psoriasis and psoriatic arthritis.
- * Recent studies indicate significant improvements in psoriasis severity, often observable as early as two weeks after treatment commencement, with maximum benefits noted between weeks 8-12.
- * Research has demonstrated that dual neutralization of IL-17A and IL-17F can better manage inflammation compared to therapies targeting IL-17A alone, highlighting IL-17F's role in chronic inflammation.
- * Bimzelx has exhibited a favorable safety profile, with most side effects being mild to moderate, and no major safety concerns have been reported in clinical trials.
- * In various clinical trials, there have been positive outcomes reported regarding symptoms of both psoriasis and psoriatic arthritis, indicating strong therapeutic potential.
- * A recent multicenter study explored the risk of candidiasis in patients treated with Bimzelx, adding to the ongoing evaluation of its safety in real-world settings.
- * As of October 2023, Bimzelx remains in advanced phases of clinical trials, particularly phase III, which focuses on its effectiveness in a broader patient population.
- * Current literature emphasizes the need for more comprehensive treatments for inflammatory conditions, with Bimzelx's dual-action mechanism representing a significant advancement in therapeutics.
- * Experts believe that continued research into Bimzelx may yield valuable insights for the management of other immune-mediated inflammatory diseases beyond psoriasis and psoriatic arthritis.
- * Overall, Bimzelx (bimekizumab) is positioned as a promising option in the evolving landscape of biologics targeting inflammatory pathways, showcasing the potential of dual inhibition in therapeutic strategies.
Bimzelx (bimekizumab)
The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Editorial: Patients-oriented treatments for chronic inflammatory skin diseases.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
A revolutionary therapeutic approach for psoriasis: bispecific biological agents.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
European League Against Rheumatism And American Diabetes Association.
London, UK
2 hours ago
1 Received
- EULAR sessions highlighted new treatments for rheumatic diseases, focusing on drugs like infliximab biosimilar, certolizumab pegol, secukinumab, and bimekizumab.
- * Significant advancements in diabetes were discussed at the ADA's Scientific Sessions, showcasing the latest research in this area.
- * The presentations provided valuable insights into both rheumatic disease treatment and diabetes management for healthcare professionals.
$100 - $150
Hourly Rate
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
London, UK
2 hours ago
1 Received
- Aims of the study were to evaluate the safety, pharmacokinetics, and effectiveness of bimekizumab, a new antibody targeting interleukin-17A and IL-17F, in patients with mild plaque psoriasis.
- The study involved 39 participants who were randomly assigned to receive either different doses of bimekizumab or a placebo, demonstrating that the drug was well-tolerated and no serious side effects occurred.
- Results showed significant improvement in psoriasis symptoms as early as 2 weeks after treatment, with maximum benefits observed between weeks 8-12, indicating strong potential for bimekizumab in treating conditions influenced by IL-17A and IL-17F.
$100 - $150
Hourly Rate
Developments with experimental and investigational drugs for axial spondyloarthritis.
London, UK
2 hours ago
1 Received
- Axial spondyloarthritis (AxSpA) is a chronic inflammatory condition that previously had few treatment options, primarily relying on TNF-α blockers.
- The introduction of Secukinumab, an anti-IL-17A monoclonal antibody, represents a significant development in the treatment landscape for AxSpA, alongside other agents targeting IL-17 and IL-23.
- Ongoing research aims to clarify the role of these new treatments in managing various aspects of AxSpA, including their effectiveness and safety over the long term.
$100 - $150
Hourly Rate
[Psoriatic arthritis : Drugs of the (near) future].
London, UK
2 hours ago
1 Received
- Psoriatic arthritis (PsA) requires targeted and effective treatment strategies due to its varied symptoms affecting both joints and skin.
- * Recent advancements in understanding PsA's pathophysiology have led to new therapies under development.
- * Promising drugs currently in phase 3 trials include tofacitinib (a Janus kinase inhibitor) and several antibodies that target the IL17-signaling pathway, along with potential new small molecules like ponesimod and CF101.
$100 - $150
Hourly Rate
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
London, UK
2 hours ago
1 Received
- - Advances in biotechnology and disease understanding have led to targeted treatments for immune-mediated inflammatory diseases (IMIDs), allowing for better therapies and insights into disease mechanisms.
- - The review discusses various novel biologic agents that target specific immune pathways, including interleukins (IL-17, IL-12/23, IL-23), type I and II interferons, and strategies to inhibit lymphocyte recruitment and JAK signaling.
- - It also highlights new treatments directed at B-cells and regulatory T-cells, as well as innovative biotechnological developments like bispecific antibodies that may improve IMID management.
$100 - $150
Hourly Rate
Emerging drugs for the treatment of axial spondyloarthritis.
London, UK
2 hours ago
1 Received
- Axial spondyloarthritis (axSpA) treatment has long relied on non-steroidal drugs and TNFα inhibitors, but with the introduction of secukinumab, new therapies are emerging to address existing gaps.
- Current trials are investigating additional drugs such as ixekizumab, bimekizumab, brodalumab targeting IL-17, and others focused on the IL-12/-23 axis and JAK inhibitors.
- Experts believe that the variety of treatment options for axSpA will expand soon, and there is a crucial need for studies to determine the best treatment strategies aligned with the treat-to-target approach.
$100 - $150
Hourly Rate
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
London, UK
2 hours ago
1 Received
- IL-17A is crucial for inflammation in immune diseases, but the role of IL-17F is less understood; the study hypothesizes that both contribute to chronic inflammation and that targeting both may be more effective.
- Preclinical tests showed that IL-17F triggers similar inflammatory reactions as IL-17A, and the clinical trial of bimekizumab (a drug neutralizing both IL-17A and IL-17F) demonstrated better inflammation control compared to targeting IL-17A alone.
- Results from the trial indicate that dual inhibition significantly improved patient outcomes in psoriatic arthritis by reducing symptoms in skin and joints, supporting the importance of IL-17F in inflammatory processes.
$100 - $150
Hourly Rate
Emerging treatment options for spondyloarthritis.
London, UK
2 hours ago
1 Received
- The management of spondyloarthritis (SpA) has evolved significantly due to the introduction of biologic disease-modifying antirheumatic drugs (bDMARDs).
- Axial SpA (axSpA) treatment options have expanded with the recent approval of secukinumab, an IL-17A inhibitor, adding to the longstanding use of TNFα inhibitors.
- Despite advances, there remains a critical need for more treatment options for axSpA and psoriatic arthritis (PsA), with various new therapies currently in development.
$100 - $150
Hourly Rate
Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology Seminar.
London, UK
2 hours ago
1 Received
- The Skin Disease Education Foundation's 42nd Annual Hawaii Dermatology Seminar® highlighted advancements in treating common skin conditions like psoriasis, focusing on the effectiveness of new therapies, including interleukin (IL)-17 antagonists and TNF inhibitors.
- Experts shared insights on the safety and efficacy of biologics, emphasizing the long-term safety of TNF inhibitors and the ongoing approval process for a new one, as well as considerations for pregnant and breastfeeding patients.
- The seminar also addressed the significance of topical treatments for psoriasis and rosacea, along with current research on isotretinoin patient monitoring, and discussed the safety of aesthetic procedures like cellulite treatments and facial fillers.
$100 - $150
Hourly Rate
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
London, UK
2 hours ago
1 Received
- Neutralizing both IL-17A and IL-17F with bimekizumab may effectively reduce inflammation in moderate-to-severe plaque psoriasis patients.
- A phase 2b study showed significant improvements in psoriasis severity, with a higher percentage of patients achieving a ≥90% reduction in symptoms compared to the placebo group.
- While most patients experienced mild to moderate side effects, bimekizumab showed favorable safety results without major safety concerns.
$100 - $150
Hourly Rate
Bimekizumab for the treatment of psoriatic disease.
London, UK
2 hours ago
1 Received
- Psoriasis and psoriatic arthritis are prevalent conditions that cause considerable physical and emotional strain, with existing treatments not working for all patients.
- Bimekizumab is a promising new biologic currently in phase III clinical trials, targeting both IL-17A and IL-17F to improve symptoms effectively.
- Early phase II studies indicate that bimekizumab can quickly alleviate symptoms, has good safety profiles, and is generally well-tolerated by patients.
$100 - $150
Hourly Rate
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.
London, UK
2 hours ago
1 Received
- Plaque psoriasis is a chronic skin condition linked to other health issues, like arthritis, and is driven by inflammation.
- Recent advances in understanding psoriasis have led to new treatment options targeting specific proteins, particularly anti-IL-17A and anti-IL-17F antibodies.
- Bimekizumab is an innovative therapy that can block both IL-17A and IL-17F and shows a unique molecular structure compared to other treatments, highlighting its potential effectiveness.
$100 - $150
Hourly Rate
Systematic review of immunomodulatory therapies for hidradenitis suppurativa.
London, UK
2 hours ago
1 Received
- Recent research has improved our understanding of immune dysregulation in moderate/severe hidradenitis suppurativa (HS), leading to the exploration of various immunomodulatory therapies.
- A systematic review of literature from multiple databases highlighted 107 articles and 35 clinical trials, indicating that adalimumab and infliximab are the most studied treatments for HS.
- While adalimumab is the only FDA-approved biologic for HS, several other agents have shown potential and further clinical trials are in progress to assess their efficacy and safety profiles.
$100 - $150
Hourly Rate
State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.
London, UK
2 hours ago
1 Received
- * Advances in understanding psoriasis have led to the creation of targeted therapies like biologics (e.g., TNF-α, IL-12/23, IL-17, and IL-23 inhibitors), which help reduce inflammation effectively.
- * The introduction of biosimilars is making these treatments more affordable, and future research aims to tailor therapies based on individual patient characteristics for better outcomes.
$100 - $150
Hourly Rate
Pharmacological development in hidradenitis suppurativa.
London, UK
2 hours ago
1 Received
- Hidradenitis suppurativa (HS) is a chronic skin condition characterized by painful nodules and abscesses in skin folds, causing significant suffering and requiring ongoing treatment.
- Despite recent advancements in treatment, there is still a significant need for effective therapies, focusing on the underlying mechanisms like inflammation and infection.
- Currently, adalimumab is the only FDA-approved treatment, but new biologics targeting specific inflammatory pathways are being researched in clinical trials for better management of HS.
$100 - $150
Hourly Rate
Treating to Target(s) With Interleukin-17 Inhibitors.
London, UK
2 hours ago
1 Received
- The treat-to-target (T2T) strategy is increasingly used in medicine for optimal treatment decisions and may be effective for managing IL-17 inhibitors in autoimmune diseases like psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- The article aims to evaluate the effectiveness and safety of IL-17 inhibitors using the T2T approach based on clinical trial evidence.
- Results indicate that IL-17 inhibitors like secukinumab and ixekizumab significantly outperform placebo and improve outcomes for psoriasis, psoriatic arthritis, and ankylosing spondylitis, with low rates of serious side effects.
$100 - $150
Hourly Rate
IL-17 inhibition in axial spondyloarthritis: current and future perspectives.
London, UK
2 hours ago
1 Received
- - The text discusses the role of interleukin (IL)-17, a key proinflammatory cytokine, in the development of ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA), highlighting its significance in the disease's immunopathogenesis.
- - It reviews the effectiveness and safety of IL-17A inhibitors like secukinumab and ixekizumab and provides insight into ongoing research on additional IL-17 inhibitors such as bimekizumab and brodalumab.
- - The expert opinion emphasizes that IL-17 inhibitors enhance treatment options for AS, demonstrating effectiveness even in patients who have not responded to tumor necrosis factor inhibitors while maintaining a reasonable safety profile.
$100 - $150
Hourly Rate